Skip to main content
OpenTrials
Completed

NCT Number: NCT02287194

SpyGlass Direct Visualization System Clinical Registry in China

To document indications for cholangioscopy and clinical utility of the SpyGlass Direct Visualization System in China when used per standard of practice.

Prospective, Post market, Multi-center, Non-randomized Study

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Biliary Tract Diseases Digestive System Diseases

Age range

18 year–85 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Shanghai Changhai Hospital

Shanghai, Shanghai Municipality, China

About this study

Patients who presenting with an indication for cholangioscopy or presenting with a possible indication for cholangioscopy to be determined during the ERCP procedure immediately preceding the SpyGlass procedure will join this study, totally 500 patients across 16 sites throughout China will participate in study. After SpyGlass operation, all patients will be followed for 72 hours to observe adverse events, and patients with indeterminate stricture or undefined filling defect indication with tissue sampling not yielding histopathology positive for malignancy and unresolved device and/or procedure related SAE at 72 Hours will continue to be followed up until 6 months. Finally, procedure success rate will be analyzed as primary endpoint, and SAEs and impact of patients management will be analyzed as secondary endpoint.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age above 18 and not above 85.
  • Willing and able to provide written informed consent to participate in the study.
  • Willing and able to comply with the study procedures.
  • Indicated for ERCP and cholangioscopy or indicated for ERCP with suspected need for cholangioscopy.

Exclusion criteria

  • Endoscopic techniques are contraindicated.
  • ERCP is contraindicated
  • A medical condition that warrants the use of the device outside of the indication for use.
  • Requirement for anticoagulation that cannot be safely stopped at least 7 days prior to the procedure.

Treatment and study plan

SpyGlass

Device

The SpyGlass Direct Visualization System is an integrated product platform that is designed to provide a direct intraluminal view of the biliary duct system and direct therapeutic devices.

Primary outcomes

  1. Procedural success rate

    Time frame: 72 hours

    • For indeterminate strictures or undefined filling defects cases procedural success is defined as 1) ability to visualize stricture or defect, and 2) ability to provide visual impression of malignancy, and 3) when applicable, ability to obtain SpyBite biopsy adequate for histology
    • For biliary stone cases procedural success is defined as 1) ability to visualize the stone(s), and 2) ability to successfully initiate stone fragmentation, and 3) ability to achieve stone clearance in one or more SpyGlass procedures.
    • For other indications procedural success is defined as ability to establish diagnosis and /or complete therapy in the following categories: 1) pre-operative assessment of extent of peri-ampullary and biliary tumors, 2) selective guidewire placement, 3) assessment of unexplained hemobilia, 4) assessment of portal biliopathy, 5) assessment of intraductal biliary ablation therapy, 6) extraction of migrated stents, or 7) other.

Secondary outcomes

  1. Safety Endpoints

    Time frame: Post Procedure

    Evaluation of serious adverse events (SAEs) related to the SpyGlass devices and/or the SpyGlass procedure from enrollment through the 72 Hour Post Procedure Follow-up Visit.

Sponsors and collaborators

Lead sponsor

Boston Scientific Corporation

Industry

Registry information

Official study title

Clinical Registry of Cholangioscopy Using the SpyGlass™ Direct Visualization System Throughout China

Acronym: SpyChina

Important dates

Study start
2014
Primary completion
2016
Study completion
2017
First posted
Nov 10, 2014
Registry last updated
Jul 31, 2018

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.